Seagen

In December 2023, Pfizer acquired Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion. The acquisition combined Seagen's leading ADC technology with Pfizer's global scale and expertise to accelerate the development of next-generation cancer treatments. The acquisition expanded Pfizer's oncology portfolio and pipeline, doubling the size of its oncology programs and strengthening its position in the cancer therapy market.